Introduction to the standard usage and dosage of Pemetinib/Dabotan

Pemigatinib(Pemigatinib) is a targeted therapy drug mainly used to treatcholangiocarcinoma (CCA) and other tumors related to FGFR gene rearrangements. Standard use and dosage of this drug are tailored to the patient's specific disease type and treatment goals.

For patients with cholangiocarcinoma (CCA), the recommended dose of pemetinib is 13.5 mg orally once daily. Patients need to be treated continuously for 14 days, and then enter a 21-day treatment cycle, which includes a 7-day drug-free period. This treatment cycle is designed to balance the antitumor effect of the drug with the management of side effects. Pemetinib inhibits the growth and spread of tumor cells by inhibiting the FGFR signaling pathway, and has been proven to effectively delay disease progression in patients with cholangiocarcinoma.

For patients with FGFR1-rearranged myeloid or lymphoid tumors, the recommended dose of pemetinib is 13.5 mg once daily, and patients should continue to take it orally until disease progression or unacceptable toxicity occurs. Under this treatment plan, patients can use pemetinib for a long time to continue to exert its targeting effect and slow down the expansion of tumors. Regardless of the indication, pemetinib should be taken strictly in accordance with the dosage regulations.

Pemetinib is administered at approximately the same time each day and the tablet should be swallowed whole without crushing, chewing or dissolving the tablet. In addition, pemetinib can be taken before or after eating and does not need to be taken with food. However, if a patient vomits while taking a dose or forgets to take a dose, they should continue taking the next dose as scheduled without taking the missed dose. If the missed dose exceeds 4 hours, the patient should skip the dose and continue taking it as planned.

Patients should undergo regular medical examinations while taking pemetinib, including monitoring of liver function, kidney function, and drug-related side effects. If discomfort occurs, patients should communicate with their doctor in time to adjust the medication regimen or deal with side effects.

Reference materials:https://go.drugbank.com/drugs/DB15102